

**DAFTAR PUSTAKA**

- Alexandru, N., Popov, D., Sbarcea, A. and Amuzescu, M., 2007. Platelet free cytosolic calcium concentration during ageing of type 2 diabetic patients. *Platelets*, vol. 18, no. 7, pp. 473–480.
- Amelia, R., Wahyuni, A.S. and Yunanda, Y., 2019. Diabetic Neuropathy among Type 2 Diabetes Mellitus Patients at Amblas Primary Health Care in Medan City. *Open Access Macedonian Journal of Medical Sciences*, vol. 7, no. 20, p. 3400.
- American Diabetes, A., 2016. Standards of Medical Care in Diabetes—2016: Summary of Revisions. *Diabetes Care*, vol. 39, no. Supplement 1, pp. S4–S5.
- Ang, L., Palakodeti, V., Khalid, A., Tsimikas, S., Idrees, Z., Tran, P., Clopton, P., Zafar, N., Bromberg-Marin, G. and Keramati, S., 2008. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. *Journal of the American College of Cardiology*, vol. 52, no. 13, pp. 1052–1059.
- Assert, R., Scherk, G., Bumbure, A., Pirags, V., Schatz, H. and Pfeiffer, A.F.H., 2001. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. *Diabetologia*, vol. 44, no. 2, pp. 188–195.
- Bansal, D., Gudala, K., Muthyalu, H., Esam, H.P., Nayakallu, R. and Bhansali, A., 2014. Prevalence and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary care setting. *Journal of diabetes investigation*, vol. 5, no. 6, pp. 714–721.
- Blázquez-Medela, A.M., García-Ortiz, L., Gómez-Marcos, M.A., Recio-Rodríguez, J.I., Sánchez-Rodríguez, A., López-Novoa, J.M. and Martínez-Salgado, C., 2010. Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. *BMC medicine*, vol. 8, no. 1, p. 86.
- BT Laboratory, 2020. *Human Advanced Glycation End Products ELISA Kit*, Shanghai, China.
- Callaghan, B.C., Cheng, H.T., Stables, C.L., Smith, A.L. and Feldman, E.L., 2012. Diabetic neuropathy: clinical manifestations and current treatments. *The lancet NEUROLOGY*, vol. 11, no. 6, pp. 521–534.
- Carrizzo, A., Izzo, C., Oliveti, M., Alfano, A., Virtuoso, N., Capunzo, M., Di Pietro, P., Calabrese, M., De Simone, E., Sciarretta, S., Frati, G., Migliarino, S., Damato, A., Ambrosio, M., De Caro, F. and Vecchione, C., 2018. The main determinants of diabetes mellitus vascular complications: Endothelial dysfunction and platelet hyperaggregation. *International Journal of Molecular Sciences*, vol. 19, no. 10, pp. 1–19.
- Chaudhuri, J., Bains, Y., Guha, S., Kahn, A., Hall, D., Bose, N., Gugliucci, A. and Kapahi, P., 2018. The Role of Advanced Glycation End Products in Aging and

- Metabolic Diseases: Bridging Association and Causality. *Cell Metabolism*, vol. 28, no. 3, pp. 337–352.
- Chawla, A., Chawla, R. and Jaggi, S., 2016. Microvascular and macrovascular complications in diabetes mellitus: distinct or continuum? *Indian journal of endocrinology and metabolism*, vol. 20, no. 4, p. 546.
- Cherney, D.Z.I., Perkins, B.A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O.E., Woerle, H.-J., von Eynatten, M. and Broedl, U.C., 2014. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. *Cardiovascular diabetology*, vol. 13, no. 1, p. 28.
- Chronolog Corporation, 2016. *Instruction Manual for the Chrono-Log Platelet Aggregometer*.
- Craig, A.B., Strauss, M.B., Daniller, A. and Miller, S.S., 2014. Foot sensation testing in the patient with diabetes: introduction of the quick & easy assessment tool. *Wounds: a compendium of clinical research and practice*, vol. 26, no. 8, pp. 221–231.
- Dhurat, R. and Sukesh, M.S., 2014. Principles and methods of preparation of platelet-rich plasma: a review and author's perspective. *Journal of cutaneous and aesthetic surgery*, vol. 7, no. 4, p. 189.
- Doğru, T., Taşçı, İ., Naharcı, M.İ., Sönmez, A., Erdem, G. and Kılıç, S., 2007. Mean platelet volume levels in metabolic syndrome. *AJCI*, vol. 1, pp. 99–105.
- Dolezelova, E., Sa, I.C.I., Prasnicka, A., Hroch, M., Hyspler, R., Ticha, A., Lastuvkova, H., Cermanova, J., Pericacho, M. and Visek, J., 2019. High soluble endoglin levels regulate cholesterol homeostasis and bile acids turnover in the liver of transgenic mice. *Life sciences*, vol. 232, p. 116643.
- Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P.D., Zieve, F.J., Marks, J., Davis, S.N. and Hayward, R., 2009. Glucose control and vascular complications in veterans with type 2 diabetes. *New England journal of medicine*, vol. 360, no. 2, pp. 129–139.
- Durachim, A. and Astuti, D., 2018. *Bahan Ajar Teknologi Laboratorium Medik : Hemostasis*, Edisi 1 Susilo, A., (ed.). Kemenkes RI, Jakarta.
- El-Khawaga, G. and Abdel-Wahab, F., 2015. Knowledge, attitudes, practice and compliance of diabetic patients in Dakahlia, Egypt. *Euro J Res Med Sci*, vol. 3, no. 1.
- El-Mesallamy, H.O., Hamdy, N.M., Ezzat, O.A. and Reda, A.M., 2011. Levels of soluble advanced glycation end product-receptors and other soluble serum markers as indicators of diabetic neuropathy in the foot. *Journal of Investigative Medicine*, vol. 59, no. 8, pp. 1233–1238.
- Erkurt, M.A., Kaya, E., Berber, I., Koroglu, M. and Kuku, I., 2012.

- Thrombocytopenia in adults. *Journal of Hematology*, vol. 1, no. 2–3, pp. 44–53.
- Fazan, V.P.S., de Vasconcelos, C.A.C., Valen  a, M.M., Nessler, R. and Moore, K.C., 2010. Diabetic Peripheral Neuropathies: A Morphometric Overview. *International Journal of Morphology*, vol. 28, no. 1.
- Feldman, E.L., 2003. Oxidative stress and diabetic neuropathy: a new understanding of an old problem. , vol. 111, no. 4, pp. 1–3.
- Ferreira, I.A., Mocking, A.I.M., Feijge, M.A.H., Gorter, G., van Haeften, T.W., Heemskerk, J.W.M. and Akkerman, J.-W.N., 2006. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. *Arteriosclerosis, thrombosis, and vascular biology*, vol. 26, no. 2, pp. 417–422.
- Ferretti, G., Rabini, R.A., Bacchetti, T., Vignini, A., Salvolini, E., Ravaglia, F., Curatola, G. and Mazzanti, L., 2002. Glycated low density lipoproteins modify platelet properties: a compositional and functional study. *The Journal of Clinical Endocrinology & Metabolism*, vol. 87, no. 5, pp. 2180–2184.
- Ferri, F.F., 2017. *Ferri's Best Test E-Book: A Practical Guide to Laboratory Medicine and Diagnostic Imaging E-Book*. Elsevier Health Sciences.
- Forbes, J.M., Soldatos, G. and Thomas, M.C., 2005. Below the Radar: Advanced Glycation End Products that Detour “around the side”: Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes? *The Clinical biochemist. Reviews/Australian Association of Clinical Biochemists.*, vol. 26, no. 4, p. 123.
- Fowler, M.J., 2008. Microvascular and macrovascular complications of diabetes. *Clinical diabetes*, vol. 26, no. 2, pp. 77–82.
- Gawaz M. Blood platelets. 1st ed. Stuttgart: Georg Thieme Verlag; 2001.p.42-9;92-3.
- Giacco, F. and Brownlee, M., 2010. Oxidative stress and diabetic complications. *Circulation research*, vol. 107, no. 9, pp. 1058–1070.
- Guthikonda, S., Alviar, C.L., Vaduganathan, M., Arikan, M., Tellez, A., DeLao, T., Granada, J.F., Dong, J.-F., Kleiman, N.S. and Lev, E.I., 2008. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. *Journal of the American College of Cardiology*, vol. 52, no. 9, pp. 743–749.
- G  ven, F.M.K., Yilmaz, A., Aydin, H. and Korkmaz, I., 2010. Platelet aggregation responses in type 2 diabetic patients. *Health*, vol. 2, no. 07, p. 708.
- Habib, A.A. and Brannagan, T.H., 2010. Therapeutic strategies for diabetic neuropathy. *Current neurology and neuroscience reports*, vol. 10, no. 2, pp. 92–100.
- Hechler, B., Cattaneo, M. and Gachet, C., 2005. The P2 receptors in platelet function. *Seminars in thrombosis and hemostasis*. 2005 Copyright   2005 by

- Thieme Medical Publishers, Inc., 333 Seventh Avenue, New ..., pp. 150–161.
- Hoffband, A., Moss, P. and Pettit, J., 2013. *Trombosit, pembekuan darah, dan hemostasis. Dalam: kapita selektif hematologi*, Edisi 6 EGC, (ed.). EGC, Jakarta.
- Hoffbrand, A.V., 2016. *Haematology*, 7th edition. Wiley Blackwell, India.
- Hvas, A.-M. and Grove, E.L., 2017. Platelet function tests: preanalytical variables, clinical utility, advantages, and disadvantages. In: *Hemostasis and Thrombosis*. Springer, pp. 305–320.
- Ikeda, Y., Matsubara, Y. and Kamata, T., 2008. Platelet immunology: structure, functions and polymorphism of membrane glycoproteins. *Platelets in hematologic and cardiovascular disorders*. (Geselle P, Fuster V, Lopez JA, Page CP, Vermeylen J, ed). Cambridge: Cambridge University Press, pp. 21–36.
- Jack, M. and Wright, D., 2012. Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy. *Translational Research*, vol. 159, no. 5, pp. 355–365.
- Jaiswal, M., Divers, J., Dabelea, D., Isom, S., Bell, R.A., Martin, C.L., Pettitt, D.J., Saydah, S., Pihoker, C. and Standiford, D.A., 2017. Prevalence of and risk factors for diabetic peripheral neuropathy in youth with type 1 and type 2 diabetes: SEARCH for Diabetes in Youth Study. *Diabetes care*, vol. 40, no. 9, pp. 1226–1232.
- Jang, C., Lim, J.H., Park, C.W. and Cho, Y.-J., 2011. Regulator of calcineurin 1 isoform 4 (RCAN1.4) is overexpressed in the glomeruli of diabetic mice. *The Korean Journal of Physiology & Pharmacology*, vol. 15, no. 5, pp. 299–305.
- Jansson, S.P.O., Fall, K., Brus, O., Magnusson, A., Wändell, P., Östgren, C.J. and Rolandsson, O., 2015. Prevalence and incidence of diabetes mellitus: a nationwide population-based pharmaco-epidemiological study in Sweden. *Diabetic medicine*, vol. 32, no. 10, pp. 1319–1328.
- Jarvis, G.E., 2004. Platelet Aggregation. In: *Platelets and Megakaryocytes*. Springer, pp. 65–76.
- Kirkman, M.S., Briscoe, V.J., Clark, N., Florez, H., Haas, L.B., Halter, J.B., Huang, E.S., Korytkowski, M.T., Munshi, M.N. and Odegard, P.S., 2012. Diabetes in older adults. *Diabetes care*, vol. 35, no. 12, pp. 2650–2664.
- Koltai, K., Kesmarky, G., Feher, G., Tibold, A. and Toth, K., 2017. Platelet aggregometry testing: Molecular mechanisms, techniques and clinical implications. *International Journal of Molecular Sciences*, vol. 18, no. 8, pp. 1–21.
- Kuate-Tegueu, C., Temfack, E., Ngankou, S., Doumbe, J., Djentcheu, V.P. and Kengne, A.P., 2015. Prevalence and determinants of diabetic polyneuropathy in a sub-Saharan African referral hospital. *Journal of the neurological sciences*, vol. 355, no. 1–2, pp. 108–112.

- Lin, M.-J., Chen, C.-Y., Lin, H.-D., Lin, C.-S. and Wu, H.-P., 2016. Prognostic significance of central pulse pressure for mortality in patients with coronary artery disease receiving repeated percutaneous coronary intervention. *Medicine*, vol. 95, no. 13.
- Lin, M.J., Chang, Y.J., Chen, C.Y., Huang, C.C., Chuang, T.Y., Wu, H.P. and Bil, J., 2019. Influence of hypercholesterolemia and diabetes on long-term outcome in patients with stable coronary artery disease receiving percutaneous coronary intervention. *Medicine (United States)*, vol. 98, no. 34.
- Linden, E., Cai, W., He, J.C., Xue, C., Li, Z., Winston, J., Vlassara, H. and Uribarri, J., 2008. Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. *Clinical Journal of the American Society of Nephrology*, vol. 3, no. 3, pp. 691–698.
- M., H., N., T., H., H., A., S., A., C., R., Nakano, H., T., R., Nakagawa, T., O., M., M., S., Y., K., N., T., K., K., T., Y., T., J., S. and Y., I., 2016. Association of advanced glycation end products with coronary artery calcification in Japanese subjects with type 2 diabetes as assessed by skin autofluorescence. *Journal of Atherosclerosis and Thrombosis*, vol. 23, no. 10, pp. 1178–1187.
- Mohammed, R., 2014. a Clinical Approach To Diabetic Peripheral Neuropathy. *Journal of Evidence Based Medicine and Healthcare*, vol. 1, no. 16, pp. 2009–2016.
- Michelson, A.D. and Furman, M.I., 2005. Markers of Platelet Activation and Granule Secretion. In: *Platelet Function*. Springer, pp. 301–314.
- Negre-Salvayre, A., Salvayre, R., Auge, N., Pamplona, R. and Portero-Otin, M., 2009. Hyperglycemia and glycation in diabetic complications. *Antioxidants & redox signaling*, vol. 11, no. 12, pp. 3071–3109.
- Nneka, N.I., Uchenna, M.A., Chinyere, E.C., Ikechukwu, E.A., Onyemaechi, O.O. and Nwobi, E.J., 2012. Platelet activity in patients with type 2 diabetes in eastern Nigeria. *Res. J. Pharmacol*, vol. 6, no. 3, pp. 48–51.
- Oesman F, Setiabudy RD. Fisiologis hemostasis dan fibrinolysis. Dalam: Setiabudy RD, Editor. Hemostasis dan Trombosis, edisi keempat. Jakarta: FKUI, 2012. h.2,3,4.
- Patel, U.D., Young, E.W., Ojo, A.O. and Hayward, R.A., 2005. CKD progression and mortality among older patients with diabetes. *American journal of kidney diseases*, vol. 46, no. 3, pp. 406–414.
- Pedreño, J., Hurt-Camejo, E., Wiklund, O., Badimaón, L. and Masana, L., 2000. Platelet function in patients with familial hypertriglyceridemia: Evidence that platelet reactivity is modulated by apolipoprotein E content of very-low-density lipoprotein particles. *Metabolism-Clinical and Experimental*, vol. 49, no. 7, pp. 942–949.
- Pop-Busui, R., Boulton, A.J.M., Feldman, E.L., Bril, V., Freeman, R., Malik, R.A., Sosenko, J.M. and Ziegler, D., 2017. Diabetic neuropathy: a position statement by the American Diabetes Association. *Diabetes care*, vol. 40, no. 1, pp. 136–

154.

- Price, S. and Wilson, L., 2005. *Gangguan Sistem Endokrin dan Metabolik*, Edisi 6  
Brahm, U. and Hartanto, H., (eds.). EGC, Jakarta.
- Riskedas, 2018. Hasil utama riskesdas 2018. *Jakarta: Kemenkes RI*.
- Sato, K., Tatsunami, R., Yama, K. and Tampo, Y., 2013. Glycolaldehyde induces cytotoxicity and increases glutathione and multidrug-resistance-associated protein levels in Schwann cells. *Biological and Pharmaceutical Bulletin*, vol. 36, no. 7, pp. 1111–1117.
- Schneider, D.J., 2009. Factors contributing to increased platelet reactivity in people with diabetes. *Diabetes care*, vol. 32, no. 4, pp. 525–527.
- Setiabudy, R.D., 2018. *Hemostasis dan Trombosis*, Edisi Keen. Setiabudy, R.D., (ed.). FK UI, Jakarta.
- Shah, M.S. and Brownlee, M., 2016. Molecular and cellular mechanisms of cardiovascular disorders in diabetes. *Circulation research*, vol. 118, no. 11, pp. 1808–1829.
- Singh, V.P., Bali, A., Singh, N. and Jaggi, A.S., 2014. Advanced glycation end products and diabetic complications. *Korean J Physiol Pharmacol*, vol. 18, pp. 1–14.
- Stanifer, J.W., Cleland, C.R., Makuka, G.J., Egger, J.R., Maro, V., Maro, H., Karia, F., Patel, U.D., Burton, M.J. and Philippin, H., 2016. Prevalence, risk factors, and complications of diabetes in the Kilimanjaro region: a population-based study from Tanzania. *PloS one*, vol. 11, no. 10, p. e0164428.
- Tarigan, T.J.E., Yunir, E., Subekti, I., Pramono, L.A. and Martina, D., 2015. Profile and analysis of diabetes chronic complications in Outpatient Diabetes Clinic of Cipto Mangunkusumo Hospital, Jakarta. *Medical Journal of Indonesia*, vol. 24, no. 3, pp. 156–162.
- Tesfaye, S., 2004. Epidemiology and etiology of diabetic peripheral neuropathies. *Adv Stud Med*, vol. 4, no. 10G, pp. S1014-1021.
- Várkonyi, T. and Kempler, P., 2008. Diabetic neuropathy: new strategies for treatment. *Diabetes, obesity and metabolism*, vol. 10, no. 2, pp. 99–108.
- Wada, R., Nishizawa, Y., Yagihashi, N., Takeuchi, M., Ishikawa, Y., Yasumura, K., Nakano, M. and Yagihashi, S., 2001. Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. *European journal of clinical investigation*, vol. 31, no. 6, pp. 513–520.
- Wada, R. and Yagihashi, S., 2005. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. *Annals of the New York Academy of Sciences*, vol. 1043, no. 1, pp. 598–604.
- Wang, Y., Beck, W., Deppisch, R., Marshall, S.M., Hoenich, N.A. and Thompson, M.G., 2007. Advanced glycation end products elicit externalization of phosphatidylserine in a subpopulation of platelets via 5-HT2A/2C receptors.

- American Journal of Physiology-Cell Physiology*, vol. 293, no. 1, pp. C328–C336.
- Wautier, J.-L. and Schmidt, A.M., 2004. Protein glycation: a firm link to endothelial cell dysfunction. *Circulation research*, vol. 95, no. 3, pp. 233–238.
- Wirawan, R., 2007. Nilai Rujukan Pemeriksaan Agregasi Trombosit dengan Adenosin Difosfat pada Orang Indonesia Dewasa Normal di Jakarta. *Majalah kedokteran Indonesia*, vol. 57, no. 7, pp. 1–8.
- World Health, O., 2016. *World health statistics 2016: monitoring health for the SDGs sustainable development goals.*, World Health Organization.
- Yagihashi, S., Mizukami, H. and Sugimoto, K., 2011. Mechanism of diabetic neuropathy : Where are we now and where to go ?, vol. 2, no. 1, pp. 18–32.
- Yang, Y., Muzny, D.M., Reid, J.G., Bainbridge, M.N., Willis, A., Ward, P.A., Braxton, A., Beuten, J., Xia, F. and Niu, Z., 2013. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. *New England Journal of Medicine*, vol. 369, no. 16, pp. 1502–1511.
- Zhu, W., Li, W. and Silverstein, R.L., 2012. Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36. *Blood, The Journal of the American Society of Hematology*, vol. 119, no. 25, pp. 6136–6144.
- Ziegler, D., Rathmann, W., Dickhaus, T., Meisinger, C. and Mielck, A., 2008. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. *Diabetes care*, vol. 31, no. 3, pp. 464–469.